What is Ritlecitinib 20 mg used for?

Ritlecitinib 20 mg is indicated for Moderate to severe alopecia areata.

Who makes Ritlecitinib 20 mg?

Ritlecitinib 20 mg is developed by Pfizer.

What development phase is Ritlecitinib 20 mg in?

Ritlecitinib 20 mg is FDA-approved (marketed).

What is the generic name of Ritlecitinib 20 mg?

ritlecitinib-20-mg is the generic (nonproprietary) name of Ritlecitinib 20 mg.

Last reviewed 2026-04-20 · How we verify

Ritlecitinib 20 mg (ritlecitinib-20-mg)

Pfizer · FDA-approved active Quality 22/100

At a glance

Generic name	ritlecitinib-20-mg
Sponsor	Pfizer
Drug class	small molecule inhibitor
Target	JAK3/STAT3 pathway
Therapeutic area	Dermatology
Phase	FDA-approved

Approved indications

Moderate to severe alopecia areata

Common side effects

No common side effects on file.

Drug interactions

Warfarin
P-glycoprotein inhibitors
P-glycoprotein inducers
Strong CYP3A4 inhibitors
Strong CYP3A4 inducers
CYP2C8 inhibitors
CYP2C8 inducers
CYP2C19 inhibitors
CYP2C19 inducers
CYP2D6 inhibitors
CYP2D6 inducers
CYP3A4 substrates

Key clinical trials

A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ritlecitinib 20 mg CI brief — competitive landscape report
Ritlecitinib 20 mg updates RSS · CI watch RSS
Pfizer portfolio CI